Sleep Disordered BreathingNCT02533999
Peak(R) vs. Electrocautery in Children Undergoing Tonsillectomy With Adenoidectomy
A study testing PEAK® Plasma System and Electrosurgery in people with Sleep Disordered Breathing, run by Nemours Children's Clinic.
Trial summary
Given the large numbers of children who undergo tonsillectomy (by the time a child is 15 years old, 13% of his/her peers will have had a tonsillectomy), the significant morbidity, and direct and indirect costs associated with absences for child from school or parent from work or other responsibilities, it is vitally… Read more about this study
- Who is it for?
- Ages 3 to 17 years
- Conditions the study is for
- Sleep Disordered Breathing
- What is being tested?
- PEAK® Plasma System and Electrosurgery
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- No sites listed yet
- Study dates
- Apr 2013to Feb 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Patients are aged 3 up to 18 years old; children younger than 3 years are excluded because of a higher risk of perioperative complications such as requiring an overnight hospitalization and dehydration after discharge resulting in an emergency department visit or hospitalization
- Clinical diagnosis of sleep disordered breathing or obstructive sleep apnea 10 or recurrent tonsillitis
- Presence of adenotonsillar hypertrophy
Who cannot join
- Diagnosis of bleeding disorders*
- Craniofacial malformation
- Previous adenotonsillectomy
- Suspected lymphoma
- Developmental delay
- Diabetes or any other disease that slows wound healing
Show all 21Show fewer
- Peritonsillar abscess
- Expressive language disorder
- Hematologic wound healing disorder or necrotizing dermatosis,
- Implanted electric device
- Mucopolysaccharidosis
- Use of nonsteroidal anti-inflammatory drugs in the two weeks prior to the surgery
- Allergy to medication(s) used in this protocol
- Other planned surgical procedure during this surgical period
- Chronic pain disorder
- Planned hospital admission
- We will use the following set of questions to evaluate for bleeding issues. If all are answered "no", then the child will be enrolled. If any are answered "yes", the child will be excluded and the family will be referred for a Hematology consult.
- Has your child been told he/she has a bleeding disorder?
- Does anyone in the child's family (grandmother, grandfather, mother, father, siblings) have a known bleeding disorder?
- Does your child have easy bruising or difficulty stopping bleeding when he/she gets a cut or scratch?
- If your child has had had surgery before, did the surgeon indicate that controlling bleeding was difficult or was your child required to come back to the hospital for bleeding control?
About this study
Official title: Assessment of 14-Day Outcomes With the Peak® Surgery System Versus the Traditional Electrocautery Method in Children Ages 3 to 18 Years Undergoing Tonsillectomy With Adenoidectomy for Sleep Disordered Breathing
Given the large numbers of children who undergo tonsillectomy (by the time a child is 15 years old, 13% of his/her peers will have had a tonsillectomy), the significant morbidity, and direct and indirect costs associated with absences for child from school or parent from work or other responsibilities, it is vitally important to identify surgical techniques which will minimize pain and serious negative outcomes. This study aims to compare a new surgical technique, PEAK® Surgery System, with electrocautery, one of the most commonly used methods for tonsillectomy with or without adenoidectomy in children 3 to 6 years old with a diagnosis of sleep-disordered breathing.
In this project, the investigator will evaluate intra-operative outcomes including, surgery time and bleeding rates, and post-operative pain scores, bleeding rates, time to resumption of normal diet and activity, analgesic type and use, and frequency of emergent visits over 14 days following surgery.
Read more
The hypothesis is that there is no difference in outcomes between the traditional extracapsular electrocautery dissection method of tonsillectomy versus the newly introduced Peak® Surgery System.
The long-term goal is to minimize pain and risk of bleeding and shorten the time to resumption of normal eating and activities in children undergoing tonsillectomy.
Read the detailed description
SPECIFIC AIMS:
- Specific Aim 1: To assess differences in pain control, assessed by validated pain scores and requirement for postoperative analgesia, during the 14-day post-operative period.
- Specific Aim 2: To assess differences in bleeding (hemorrhage) both intraoperatively and 24 hours post-surgery (immediate period) and between 24 hours and 14 days post-operatively (delayed period).
- Specific Aim 3: To assess differences in other outcomes (time to resumption of normal diet and activities) and adverse events (emergent visits for medical care) between 24 hours and 14 days post-operatively.
BACKGROUND AND SIGNIFICANCE:
Epidemiology of Tonsillectomy in Children. Tonsillectomy is the second most commonly performed procedure in children under 15 years old, second to myringotomy and pressure equalization tube placement. It is estimated that 583,000 outpatient tonsillectomy procedures were performed in children in the US in 2006 accounting for 16% of all ambulatory surgeries with the greatest number (103/10,000) in children ages 0 to 6 years old. In this age group, diagnosis of airway obstruction or sleep disturbance accounts for the majority of surgery indications and tonsillectomy with adenoidectomy account for 90% of the procedures performed (vs. 10% for tonsillectomy alone). Nemours Jacksonville surgeons performed 995 tonsillectomies with/without adenoidectomy at Wolfson Children's Hospital in children 3 to 6 years old with sleep-disordered breathing from 2010-2011.
In this project, the investigators will compare electrocautery surgical method with the PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc), a recently marketed device. There are no published studies comparing the PEAK® system with other traditional methods of performing adenotonsillectomy. Nemours otolaryngologists currently use the PEAK® system for adenotonsillectomies in children 3 to 18 years of age with a diagnosis of sleep-disordered breathing. The PEAK® system generates plasma, "an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down". The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. Data from the Medtronic website indicates the temperature profile from the PEAK® system to be approximately half that associated electrosurgery at similar cut settings; and human studies indicate a 66% to 80% reduction in thermal injury depth.
PRELIMINARY STUDIES:
There are no preliminary data from Nemours using the Peak® Plasma System.
APPROACH:
- Study Design This is a prospective, randomized, single-blind controlled study. Patients and caregivers and the study coordinator will be blinded to the surgical method.
This project will involve a single study visit and 6 phone calls and completion of daily diaries for 14 days following surgery and completion of the Glasgow Children's Benefit Inventory 7 6-months after surgery. Parents and caregivers will be contacted after the surgery date is scheduled to discuss the project and determine interest. If interested, and inclusion/exclusion criteria are met, families will be advised of the study and invited to participate. Parental permission will be obtained from the parent/caregiver prior to surgery. Children aged 3 to 18 years old will be included.
Stopping Criteria: The study will be stopped and unblinded if the rate of postoperative hemorrhage, defined as Level II or Level III, exceeds 2 participants in the same surgical group assessed during the first 5-days post-operatively after the first 30 patients have been enrolled. Post-operative bleeding will be defined as follows:
Level I. All children who report to have any history of postoperative hemorrhage, whether or not there is clinical evidence.
Level II. All children who require inpatient admission for postoperative hemorrhage regardless of the need for operative intervention. This level excludes children undergoing evaluation in the emergency department for reported postoperative hemorrhage who have no evidence of clot formation or hemorrhage and are deemed safe for discharge.
Level III. All children who require a return to the operating department for control of postoperative bleeding.
Patients will be instructed to call the clinic if there is more than one tablespoon of blood in a single episode or persistent bleeding of small amounts throughout the day. Administration of dexamethasone perioperatively has been found to not increase the risk of Level II or Level III bleeds in a recent study.
Randomization Children will be randomized in a block design such that an equal number of children are randomized to electrocautery or PEAK® Plasma System for each surgeon. Caregivers will be blinded to surgical technique. The surgeon will have no input into which device a child is randomized. The study coordinator will be blinded as to which device the child was randomized.
Surgical Techniques and Post-Operative Care Surgical Procedure: Patients will be prepped as usual for routine adenotonsillectomy procedure. The procedure will be performed under general anesthesia by a fellowship trained pediatric anesthesiologist. All patients will receive 0.5mg/kg dose of intravenous dexamethasone (maximum 15mg) 11 at the onset of the procedure. Patients requiring adenoidectomy will undergo either curette removal followed by suction electrocautery or ablation by suction electrocautery alone. Adenoidectomy technique will be based upon the size of the adenoid pad where enlarged adenoids routinely employ the curette.
Most children in this age group will receive a premedication of midazolam 0.5 mg/kg prn for anxiety. General anesthesia will be induced by face mask, with sevoflurane, nitrous oxide and oxygen. A peripheral IV will be started and intravenous fentanyl (1-2 ug/kg) will be administered. Propofol may be administered at the discretion of the anesthesiologist. The patient's trachea will be intubated under direct laryngoscopy. The patient will also receive IV dexamethasone, ondansetron, and additional fentanyl, if needed. The maintenance anesthetic will include desflurane, with nitrous oxide and oxygen. At the end of the surgery the patient's trachea will be extubated when the patient is awake. Post-op rescue analgesics will include fentanyl and /or morphine.
Instrument Settings: Settings and methods for electrocautery and the PEAK® Plasma System will be standardized between the surgeons. For the PEAK® Plasma System, the setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting. For electrocautery, the setting will be standardized to 12 for tonsils and 30 for adenoids.
Data Collected Intra-operatively Total blood loss will be determined by the method described by Walner, et al in which the operating nurse will record the blood loss based on the amount in the suction canister or suction tubing at the conclusion of each procedure. Data extraction of blood loss from the operative report will be performed by the data entry specialist and not the study coordinator to prevent unblinding of the study coordinator. The Biomedical Research Department has several highly trained data entry specialists who extract clinical data from the EHR.
Data Collected Post-operatively Parents will complete a diary card beginning on the day of surgery and continuing for 14 days. After 30±4 days following surgery, the study coordinator will contact parent of each patient by telephone to obtain information on incidence of late-complications and to collect a global assessment of the parent's perception of the 30-day postoperative period. Assessment will consist of asking parents to state whether their child's pain had been less, the same, or more than they had expected it to be after the adenotonsillectomy. At this assessment, the coordinator and parents will still be blinded to the treatment received. At six-months post-operatively, parents will be mailed the Glasgow Children's Benefit Inventory (GCBI). Unblinding information will be mailed to parents 2 weeks after the GCBI has been mailed.
The following measures will be collected daily on the diary card beginning on Day 0 (day of surgery):
- Presence of bleeding. Post-operative bleeding will be scored as follows:
- Level I. All children who report to have any history of postoperative hemorrhage, whether or not there is clinical evidence.
- Level II. All children who require inpatient admission for postoperative hemorrhage regardless of the need for operative intervention. This level excludes children undergoing evaluation in the emergency department for reported postoperative hemorrhage who have no evidence of clot formation or hemorrhage and are deemed safe for discharge.
- Level III. All children who require a return to the operating department for control of postoperative bleeding. Children who return to the emergency department (ED) or hospital who are subsequently diagnosed with Von Willebrand's disease will be excluded from the study and will not be included in the data analysis.
- Assessment of subjective pain. The child will be asked by the parent to grade severity of pain daily using the Wong-Baker FACES pain rating scale 13 in the morning before eating, drinking, or taking analgesics. The Wong-Baker FACES pain rating scale is a 0 to 10 numerical rating scale (0, 2, 4, 6, 8, 10) with faces indicating the level of pain from a happy face at a score of 0 to a crying face at a score of 10. The scale is recommended for children 3 years and older.
- Type and frequency of pain medication will be recorded.
- Return to normal diet. Normal diet is defined as consumption of the types and amount of food such that another family member would not be able to recognize that the patient had undergone throat surgery. Dietary progression from liquid to soft and solid food will be also documented. Diet will be scored as 1, liquids and soft diet only; 2, some solids; 3, mostly solids; and 4, normal diet.
- Return to normal activity. Normal activity is defined as carrying out the same types and amounts of daily activity as before surgery, even if still associated with fatigue. Activity will be scored as 1, none; 2, very little; 3, mostly normal; 4, normal.
- At each post-operative phone call, the study coordinator will collect data regarding bleeding events with the questions below and document parental phone calls or visits to physician regarding parental concerns over child's recovery.
Data Collected After 6-Months Six months following surgery, parents will be mailed the Glasgow Children's Benefit Inventory (GCBI) 7. The GCBI is a post intervention health-related benefit measure consisting of 24 broadly worded yes/no questions that are applicable to any area of pediatric medicine. The GCBI scores will be compared between surgical techniques. The two study groups will be matched for age and sex.
- Conditions
- Sleep Disordered Breathing
- Being tested
- PEAK® Plasma System, Electrosurgery
- Medical subject headings
- Sleep Apnea Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PEAK® Plasma SystemDevice
Surgical method for tonsillectomy and adenoidectomy.
ElectrosurgeryDevice
Surgical method for tonsillectomy and adenoidectomy.
| Study group | Role | What they receive |
|---|---|---|
| Surgical Instrument | Experimental | PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, "an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down". The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting. Receives: Device: PEAK® Plasma System |
| Electrosurgery | Active comparator | Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids. Receives: Device: Electrosurgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Control Assessed by Validated Pain Scores: Days to Having no Pain Following Surgery
To assess differences in pain control, assessed by validated pain scores and requirement for postoperative analgesia, during the 14-day post-operative period in children ages 3 to 18 years undergoing adenotonsillectomy with a clinical diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method.
Assessment of subjective pain. The child will be asked by the parent to grade severity of pain daily using the Wong-Baker FACES pain rating scale in the morning before eating, drinking, or taking analgesics. The Wong-Baker FACES pain rating scale is a 0 to 10 numerical rating scale (0, 2, 4, 6, 8, 10) with faces indicating the level of pain from a happy face at a score of 0 to a crying face at a score of 10. The scale is recommended for children 3 years and older.
Type and frequency of pain medication will be recorded.
Measured: during the 14-day post-operative period
Secondary outcomes (5)
Number of Participants Who Experienced Bleeding Intraoperatively and 24 Hours Post-surgery (Primary Period)
To assess differences in bleeding (hemorrhage) rate (either Level I, Level II, or Level III) intraoperatively and 24 hours post-surgery (primary period) in children ages 3 to 18 years undergoing adenotonsillectomy with a diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method.
Post-operative bleeding will be scored as follows:
Level I. All children who report to have any history of postoperative hemorrhage, whether or not there is clinical evidence.
Level II. All children who require inpatient admission for postoperative hemorrhage regardless of the need for operative intervention.
Level III. All children who require a return to the operating department for control of postoperative bleeding.
Measured: intraoperatively and 24 hours post-surgery (primary period)
Number of Participants Who Experienced Bleeding Between 24 Hours and 14 Days Post-operatively (Secondary Period)
To assess differences in bleeding (hemorrhage) rate (either Level I, Level II, or Level III) between 24 hours and 14 days post-operatively (secondary period) in children ages 3 to 18 years undergoing adenotonsillectomy with a diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method.
Post-operative bleeding will be scored as follows:
Level I. All children who report to have any history of postoperative hemorrhage, whether or not there is clinical evidence.
Level II. All children who require inpatient admission for postoperative hemorrhage regardless of the need for operative intervention. Level III. All children who require a return to the operating department for control of postoperative bleeding.
Measured: between 24 hours and 14 days post-operatively (secondary period)
Days to Resumption of Normal Diet
To assess differences in other outcomes (time to resumption of normal diet) from discharge to 14 days post-operatively in children ages 3 to 18 years undergoing adenotonsillectomy with a diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method.
Return to normal diet. Normal diet is defined as consumption of the types and amount of food such that another family member would not be able to recognize that the patient had undergone throat surgery. Dietary progression from liquid to soft and solid food will be also documented. Diet will be scored as 1, liquids and soft diet only; 2, some solids; 3, mostly solids; and 4, normal diet.
Measured: from discharge to 14 days post-operatively
Days to Resumption of Normal Activities
To assess differences in other outcomes (time to resumption of normal activities) from discharge to 14 days post-operatively in children ages 3 to 18 years undergoing adenotonsillectomy with a diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method.
Return to normal activity. Normal activity is defined as carrying out the same types and amounts of daily activity as before surgery, even if still associated with fatigue. Activity will be scored as 1, none; 2, very little; 3, mostly normal; 4, normal.
Measured: from discharge to 14 days post-operatively
Adverse Events (Emergent Visits for Medical Care)
To assess differences in adverse events (emergent visits for medical care) from discharge to 14 days post-operatively in children ages 3 to 18 years undergoing adenotonsillectomy with a diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method.
Measured: from discharge to 14 days post-operatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2015 (estimated)
- Study startApr 2013
- Primary completionAug 2015
- Study completionFeb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Sleep Disordered BreathingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nemours Children's Clinic
- Sponsor type
- University, hospital or other
- Collaborators
- Baptist Health Wolfson Children's Hospital, Baptist Health Wolfson Surgery Center
- Responsible party
- Principal investigator, Kathryn Blake, PharmD, Nemours Children's Clinic
- Investigators
- Kathryn Blake, PharmD, Principal investigator, Nemours Children's Specialty Care
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02533999
- Sponsor's protocol ID
- 13-13
- Status last verified
- Feb 2018
- First submitted
- 21 Aug 2015
- Last updated
- 22 Feb 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of 14-Day Outcomes With the Peak® Surgery System Versus the Traditional Electrocautery Method in Children Ages 3 to 18 Years Undergoing Tonsillectomy With Adenoidectomy for Sleep Disordered Breathing
- ClinicalTrials.gov ID
- NCT02533999
- Acronym / sponsor ID
- 13-13
- Conditions
- Sleep Disordered Breathing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 75 participants (actual)
- Lead sponsor
- Nemours Children's ClinicUniversity, hospital or other
- Collaborators
- Baptist Health Wolfson Children's Hospital, Baptist Health Wolfson Surgery Center
- Study start
- Apr 2013
- Primary completion
- Aug 2015 (actual)
- Study completion
- Feb 2016 (actual)
- First posted
- 27 Aug 2015 (estimated)
- Results
- Posted 22 Feb 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Given the large numbers of children who undergo tonsillectomy (by the time a child is 15 years old, 13% of his/her peers will have had a tonsillectomy), the significant morbidity, and direct and indirect costs associated with absences for child from school or parent from work or other responsibilities, it is vitally important to identify surgical techniques which will minimize pain and serious negative outcomes. This study aims to compare a new surgical technique, PEAK® Surgery System, with electrocautery, one of the most commonly used methods for tonsillectomy with or without adenoidectomy in children 3 to 6 years old with a diagnosis of sleep-disordered breathing.
In this project, the investigator will evaluate intra-operative outcomes including, surgery time and bleeding rates, and post-operative pain scores, bleeding rates, time to resumption of normal diet and activity, analgesic type and use, and frequency of emergent visits over 14 days following surgery.
The hypothesis is that there is no difference in outcomes between the traditional extracapsular electrocautery dissection method of tonsillectomy versus the newly introduced Peak® Surgery System.
The long-term goal is to minimize pain and risk of bleeding and shorten the time to resumption of normal eating and activities in children undergoing tonsillectomy.
Detailed description
SPECIFIC AIMS:
- Specific Aim 1: To assess differences in pain control, assessed by validated pain scores and requirement for postoperative analgesia, during the 14-day post-operative period.
- Specific Aim 2: To assess differences in bleeding (hemorrhage) both intraoperatively and 24 hours post-surgery (immediate period) and between 24 hours and 14 days post-operatively (delayed period).
- Specific Aim 3: To assess differences in other outcomes (time to resumption of normal diet and activities) and adverse events (emergent visits for medical care) between 24 hours and 14 days post-operatively.
BACKGROUND AND SIGNIFICANCE:
Epidemiology of Tonsillectomy in Children. Tonsillectomy is the second most commonly performed procedure in children under 15 years old, second to myringotomy and pressure equalization tube placement. It is estimated that 583,000 outpatient tonsillectomy procedures were performed in children in the US in 2006 accounting for 16% of all ambulatory surgeries with the greatest number (103/10,000) in children ages 0 to 6 years old. In this age group, diagnosis of airway obstruction or sleep disturbance accounts for the majority of surgery indications and tonsillectomy with adenoidectomy account for 90% of the procedures performed (vs. 10% for tonsillectomy alone). Nemours Jacksonville surgeons performed 995 tonsillectomies with/without adenoidectomy at Wolfson Children's Hospital in children 3 to 6 years old with sleep-disordered breathing from 2010-2011.
In this project, the investigators will compare electrocautery surgical method with the PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc), a recently marketed device. There are no published studies comparing the PEAK® system with other traditional methods of performing adenotonsillectomy. Nemours otolaryngologists currently use the PEAK® system for adenotonsillectomies in children 3 to 18 years of age with a diagnosis of sleep-disordered breathing. The PEAK® system generates plasma, "an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down". The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. Data from the Medtronic website indicates the temperature profile from the PEAK® system to be approximately half that associated electrosurgery at similar cut settings; and human studies indicate a 66% to 80% reduction in thermal injury depth.
PRELIMINARY STUDIES:
There are no preliminary data from Nemours using the Peak® Plasma System.
APPROACH:
- Study Design This is a prospective, randomized, single-blind controlled study. Patients and caregivers and the study coordinator will be blinded to the surgical method.
This project will involve a single study visit and 6 phone calls and completion of daily diaries for 14 days following surgery and completion of the Glasgow Children's Benefit Inventory 7 6-months after surgery. Parents and caregivers will be contacted after the surgery date is scheduled to discuss the project and determine interest. If interested, and inclusion/exclusion criteria are met, families will be advised of the study and invited to participate. Parental permission will be obtained from the parent/caregiver prior to surgery. Children aged 3 to 18 years old will be included.
Stopping Criteria: The study will be stopped and unblinded if the rate of postoperative hemorrhage, defined as Level II or Level III, exceeds 2 participants in the same surgical group assessed during the first 5-days post-operatively after the first 30 patients have been enrolled. Post-operative bleeding will be defined as follows:
Level I. All children who report to have any history of postoperative hemorrhage, whether or not there is clinical evidence.
Level II. All children who require inpatient admission for postoperative hemorrhage regardless of the need for operative intervention. This level excludes children undergoing evaluation in the emergency department for reported postoperative hemorrhage who have no evidence of clot formation or hemorrhage and are deemed safe for discharge.
Level III. All children who require a return to the operating department for control of postoperative bleeding.
Patients will be instructed to call the clinic if there is more than one tablespoon of blood in a single episode or persistent bleeding of small amounts throughout the day. Administration of dexamethasone perioperatively has been found to not increase the risk of Level II or Level III bleeds in a recent study.
Randomization Children will be randomized in a block design such that an equal number of children are randomized to electrocautery or PEAK® Plasma System for each surgeon. Caregivers will be blinded to surgical technique. The surgeon will have no input into which device a child is randomized. The study coordinator will be blinded as to which device the child was randomized.
Surgical Techniques and Post-Operative Care Surgical Procedure: Patients will be prepped as usual for routine adenotonsillectomy procedure. The procedure will be performed under general anesthesia by a fellowship trained pediatric anesthesiologist. All patients will receive 0.5mg/kg dose of intravenous dexamethasone (maximum 15mg) 11 at the onset of the procedure. Patients requiring adenoidectomy will undergo either curette removal followed by suction electrocautery or ablation by suction electrocautery alone. Adenoidectomy technique will be based upon the size of the adenoid pad where enlarged adenoids routinely employ the curette.
Most children in this age group will receive a premedication of midazolam 0.5 mg/kg prn for anxiety. General anesthesia will be induced by face mask, with sevoflurane, nitrous oxide and oxygen. A peripheral IV will be started and intravenous fentanyl (1-2 ug/kg) will be administered. Propofol may be administered at the discretion of the anesthesiologist. The patient's trachea will be intubated under direct laryngoscopy. The patient will also receive IV dexamethasone, ondansetron, and additional fentanyl, if needed. The maintenance anesthetic will include desflurane, with nitrous oxide and oxygen. At the end of the surgery the patient's trachea will be extubated when the patient is awake. Post-op rescue analgesics will include fentanyl and /or morphine.
Instrument Settings: Settings and methods for electrocautery and the PEAK® Plasma System will be standardized between the surgeons. For the PEAK® Plasma System, the setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting. For electrocautery, the setting will be standardized to 12 for tonsils and 30 for adenoids.
Data Collected Intra-operatively Total blood loss will be determined by the method described by Walner, et al in which the operating nurse will record the blood loss based on the amount in the suction canister or suction tubing at the conclusion of each procedure. Data extraction of blood loss from the operative report will be performed by the data entry specialist and not the study coordinator to prevent unblinding of the study coordinator. The Biomedical Research Department has several highly trained data entry specialists who extract clinical data from the EHR.
Data Collected Post-operatively Parents will complete a diary card beginning on the day of surgery and continuing for 14 days. After 30±4 days following surgery, the study coordinator will contact parent of each patient by telephone to obtain information on incidence of late-complications and to collect a global assessment of the parent's perception of the 30-day postoperative period. Assessment will consist of asking parents to state whether their child's pain had been less, the same, or more than they had expected it to be after the adenotonsillectomy. At this assessment, the coordinator and parents will still be blinded to the treatment received. At six-months post-operatively, parents will be mailed the Glasgow Children's Benefit Inventory (GCBI). Unblinding information will be mailed to parents 2 weeks after the GCBI has been mailed.
The following measures will be collected daily on the diary card beginning on Day 0 (day of surgery):
- Presence of bleeding. Post-operative bleeding will be scored as follows:
- Level I. All children who report to have any history of postoperative hemorrhage, whether or not there is clinical evidence.
- Level II. All children who require inpatient admission for postoperative hemorrhage regardless of the need for operative intervention. This level excludes children undergoing evaluation in the emergency department for reported postoperative hemorrhage who have no evidence of clot formation or hemorrhage and are deemed safe for discharge.
- Level III. All children who require a return to the operating department for control of postoperative bleeding. Children who return to the emergency department (ED) or hospital who are subsequently diagnosed with Von Willebrand's disease will be excluded from the study and will not be included in the data analysis.
- Assessment of subjective pain. The child will be asked by the parent to grade severity of pain daily using the Wong-Baker FACES pain rating scale 13 in the morning before eating, drinking, or taking analgesics. The Wong-Baker FACES pain rating scale is a 0 to 10 numerical rating scale (0, 2, 4, 6, 8, 10) with faces indicating the level of pain from a happy face at a score of 0 to a crying face at a score of 10. The scale is recommended for children 3 years and older.
- Type and frequency of pain medication will be recorded.
- Return to normal diet. Normal diet is defined as consumption of the types and amount of food such that another family member would not be able to recognize that the patient had undergone throat surgery. Dietary progression from liquid to soft and solid food will be also documented. Diet will be scored as 1, liquids and soft diet only; 2, some solids; 3, mostly solids; and 4, normal diet.
- Return to normal activity. Normal activity is defined as carrying out the same types and amounts of daily activity as before surgery, even if still associated with fatigue. Activity will be scored as 1, none; 2, very little; 3, mostly normal; 4, normal.
- At each post-operative phone call, the study coordinator will collect data regarding bleeding events with the questions below and document parental phone calls or visits to physician regarding parental concerns over child's recovery.
Data Collected After 6-Months Six months following surgery, parents will be mailed the Glasgow Children's Benefit Inventory (GCBI) 7. The GCBI is a post intervention health-related benefit measure consisting of 24 broadly worded yes/no questions that are applicable to any area of pediatric medicine. The GCBI scores will be compared between surgical techniques. The two study groups will be matched for age and sex.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Surgical Instrument | Experimental | Device: PEAK® Plasma SystemPEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, "an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down". The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting. |
| Electrosurgery | Active comparator | Device: ElectrosurgeryElectrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids. |
Who may qualify
- Ages
- 3 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Patients are aged 3 up to 18 years old; children younger than 3 years are excluded because of a higher risk of perioperative complications such as requiring an overnight hospitalization and dehydration after discharge resulting in an emergency department visit or hospitalization
- Clinical diagnosis of sleep disordered breathing or obstructive sleep apnea 10 or recurrent tonsillitis
- Presence of adenotonsillar hypertrophy
Key exclusion criteria (21 listed)
- Diagnosis of bleeding disorders*
- Craniofacial malformation
- Previous adenotonsillectomy
- Suspected lymphoma
- Developmental delay
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PEAK® Plasma SystemSurgical method for tonsillectomy and adenoidectomy. | Device | Surgical Instrument |
| ElectrosurgerySurgical method for tonsillectomy and adenoidectomy. | Device | Electrosurgery |
Primary outcome
Pain Control Assessed by Validated Pain Scores: Days to Having no Pain Following Surgery
Time frame: during the 14-day post-operative period
To assess differences in pain control, assessed by validated pain scores and requirement for postoperative analgesia, during the 14-day post-operative period in children ages 3 to 18 years undergoing adenotonsillectomy with a clinical diagnosis of sleep-disordered breathing using the traditional Extracapsular Electrocautery Dissection Method versus the Peak® Surgery System Method. Assessment of subjective pain. The child will be asked by the parent to grade severity of pain daily using the Wong-Baker FACES pain rating scale in the morning before eating, drinking, or taking analgesics. The Wong-Baker FACES pain rating scale is a 0 to 10 numerical rating scale (0, 2, 4, 6, 8, 10) with faces indicating the level of pain from a happy face at a score of 0 to a crying face at a score of 10. The scale is recommended for children 3 years and older. Type and frequency of pain medication will be recorded.
5 secondary outcomes
Number of Participants Who Experienced Bleeding Intraoperatively and 24 Hours Post-surgery (Primary Period)
Time frame: intraoperatively and 24 hours post-surgery (primary period)
Number of Participants Who Experienced Bleeding Between 24 Hours and 14 Days Post-operatively (Secondary Period)
Time frame: between 24 hours and 14 days post-operatively (secondary period)
Days to Resumption of Normal Diet
Time frame: from discharge to 14 days post-operatively
Days to Resumption of Normal Activities
Time frame: from discharge to 14 days post-operatively
Adverse Events (Emergent Visits for Medical Care)
Time frame: from discharge to 14 days post-operatively
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Feb 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Sleep Disordered Breathing
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
RecruitingObservational study
Prediction of Tongue Base Obstruction During Sleep
Obstructive Sleep Disordered Breathing
RecruitingObservational study
Characterization of the Tongue in Children With Obstructive Sleep-disordered Breathing
Obstructive Sleep Disordered Breathing
Not yet recruitingObservational study
Registry of Central Sleep Apnea Patients Undergoing remedē System Implant
Central Sleep Apnea (Diagnosis), Central Sleep Apnea Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kathryn Blake, PharmD principal investigator
Nemours Children's Specialty Care
Questions about this trial
What is this clinical trial studying?
A study testing PEAK® Plasma System and Electrosurgery in people with Sleep Disordered Breathing, run by Nemours Children's Clinic.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Feb 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Control Assessed by Validated Pain Scores: Days to Having no Pain Following Surgery (time frame: during the 14-day post-operative period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2018.